Praxis Precision Medicines Dividends and Buybacks
Dividend criteria checks 0/6
Praxis Precision Medicines does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-28.2%
Buyback Yield
| Total Shareholder Yield | -28.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PRAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRAX's dividend payments have been increasing.
Dividend Yield vs Market
| Praxis Precision Medicines Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PRAX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (PRAX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PRAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PRAX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PRAX has not reported any payouts.